FOLKS ASKING WHEN, see below more DD , our TIME HAS COME.
--
1. WED, 12/2 it comes out (below)
2. Note: it states happened on Monday 11/30
3. Read the KEY STATEMENT in RED Below. Folks CHANGE OF CONTROL VALIDATION is what Charles needs to be the CEO with OTC Markets.
4. They did it on MOnday 11/30 , ONCE done then it is FINALIZED on the Structure , and shares are where they belong and with who ever.
5. If you look up the difference between Preferred A Shares and Preferred B Shares , you will see where B Shares usually signify
Quote
"Series A, B, C Funding: How It Works - Investopediawww.investopedia.com › articles › personal-finance › s...
Mar 5, 2020 — Series B funding is used to grow the company so that it can meet these levels of demand. Series B appears similar to Series A in terms of the processes and key players. ... The difference with Series B is the addition of a new wave of other venture capital firms that specialize in later-stage investing."
===================
--
ENZOLYTICS, INC.
SUPPLEMENTAL REPORT
SUBSEQUENT EVENTS
December 2, 2020
Business Combination Agreement with Bioclonetics Immunotherapeutics, Inc. Resulting in
Change of Control
-
On November 30, 2020, Enzolytics, Inc. (the “Company”) entered into a Business Combination
Agreement with Bioclonetics Immunotherapeutics, Inc., (“Bioclonetics”) a Texas Corporation
controlled by Charles S. Cotropia, the Company’s current Chief Executive Officer.
As consideration for the Business Combination, and in exchange for 100% of the issued and
outstanding stock of BioClonetics, the Company has agreed to issue a total of 204,430,000 newly
issued shares of Series B Preferred Stock to Charles S. Cotropia, and others Bioclonetics Designees
and 90,570,000 shares of newly issued Series B Preferred Stock to Harry Zhabilov, the Company’s
current Chief Financial Officer.
--
Control Block Transfer Agreement
In addition, on November 30, 2020, the Zhabilov Trust, the Company’s Controlling Shareholder,
entered into a Control Block Transfer Agreement, under which the Zhabilov Trust has agreed to
transfer 35,100,000 shares of Series A Preferred Stock and 231,000,000 shares of Common Stock
(together the “Control Block”) to Charles S. Cotropia and other Bioclonetics Designees.
( KEY NOTE )
Once such share issuances and transfers are completed, Charles S. Cotropia will be the Company’s
new Control Block holder and majority shareholder, in addition to his role as Chief Executive
Officer of Enzolytics, Inc., resulting in a Change of Control.
--
Formation of Two New Wholly-Owned Subsidiaries
Pursuant to the terms of the Business Combination Agreement, on November 24, 2020, the
Company formed two new Texas corporations as wholly-owned subsidiaries for the purpose of
licensing certain patented technologies: Biogenysis, Inc. and Virogentics, Inc.
--
Two Patent License Agreements
On November 30, 2020, Biogenysis, Inc., a wholly-owned subsidiary of Enzolytics, Inc., entered
into a Patent License Agreement with Bioclonetics in order to license the U.S. Provisional Patent
Application No. 63/078,482, filed September 15, 2020, entitled NOVEL HIV-BINDING
PEPTIDES for treating, preventing and reducing the risks of HIV, including all patents issuing
therefrom and any foreign counterparts thereof.
-
Also on November 30, 2020, Virogentics, Inc., a wholly-owned subsidiary of Enzolytics, Inc.,
entered into a Patent License Agreement with the Zhabilov Trust in order to license the U.S. Patent
No. 7,479538, entitled Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical
composition the same for detecting preventing and treating HIV; U.S. Patent No. 8,066982,
Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition compressing the
same for detecting preventing and treating HIV, including all patents issuing therefrom and any
foreign counterparts thereof.
